ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models

Cancer Communications

article

Emma Polonio-Alcalá¹  Sònia Solé-Sánchez³  Pau Muñoz-Guardiola³  Elisabet Megías-Roda³  Héctor Perez-Montoyo³  Marc Yeste-Velasco³  Jose Alfón³  Jose Miguel Lizcano⁴  Carles Domènech³  Santiago Ruiz-Martínez¹  Teresa Puig¹ 

[1] New Therapeutic Targets Laboratory ,(TargetsLab)—Oncology Unit, Department of Medical Sciences, University of Girona;Product, Process and Production Engineering Research Group ,(GREP), Department of Mechanical Engineering and Industrial Construction, University of Girona;Ability Pharmaceuticals;Protein Kinases and Signal Transduction Laboratory, Department de Bioquímica i Biologia Molecular and Institut de Neurociències, Universitat Autònoma de Barcelona

关键词: ABTL0812;    TRIB3;    Autophagy;    Breast Cancer;    Targeted Therapy;    Chemoresistance;   

DOI  :  10.1002/cac2.12282

学科分类：社会科学、人文和艺术（综合）

来源: Springer

【 摘 要 】

Triple-negative breast cancer (TNBC) accounts for 20%of all breast carcinomas and lacks a validated targeted therapy; thus, currently, cytotoxic chemotherapy is the treatment of choice [1]. Compared with other breast cancertypes, patients with TNBC are younger, have larger tumors,a higher risk of metastasis, and a higher rate of recurrence[2]. Among all the subtypes described by Lehmann et al.[3], mesenchymal-like and mesenchymal stem-like (MSL)subtypes had the lowest 5-year distant metastasis-free survival rates. Therefore, the aggressiveness and poor prognosis of TNBC call for new and more effective therapies.

【 授权许可】

CC BY|CC BY-NC-ND